Cephalosporin Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cephalosporin market size has grown steadily in recent years. It will grow from $17.69 billion in 2024 to $18.33 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to growing prevalence of bacterial infections, increasing antibiotic resistance, expanding surgical procedures and hospitalizations, rising awareness among healthcare professionals, regulatory support for antibiotic development.

The cephalosporin market size is expected to see steady growth in the next few years. It will grow to $21.05 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to escalating global burden of infectious diseases, emerging bacterial resistance, continued growth in surgical interventions and healthcare-associated infections, increasing demand for broad-spectrum antibiotics, evolving reimbursement policies influencing market dynamics. Major trends in the forecast period include technological advancements, regulatory landscape, market expansion with advance solution, collaborations and partnerships.

The anticipated increase in infectious diseases is poised to drive the growth of the cephalosporin market in the future. Infectious diseases encompass illnesses caused by the invasion and multiplication of pathogenic microorganisms, such as bacteria, viruses, fungi, and parasites. These diseases, including tuberculosis, malaria, and flu, contribute to the demand for cephalosporin antibiotics. Cephalosporins play a crucial role in managing and combating bacterial infections associated with various types of infections. For example, a report from the Centers for Disease Control and Prevention in March 2023 indicated a rise in tuberculosis (TB) cases in the United States, reaching 8,300 cases in 2022 compared to 7,874 cases in 2021. Thus, the growing prevalence of infectious diseases is expected to fuel the growth of the cephalosporin market.

The increase in healthcare expenditures is set to propel the growth of the cephalosporin market. Healthcare expenditures encompass all costs related to providing health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. Higher healthcare expenditures contribute to the cephalosporin market by enhancing accessibility and affordability, as well as fostering research, development, and innovation in antibiotic treatments. The Centers for Medicare & Medicaid Services reported in December 2023 that US healthcare spending rose by 4.1% to $4.5 trillion, or $13,493 per person in 2022, accounting for 17.3% of the country's gross domestic product. Consequently, the rise in healthcare expenditures is driving the growth of the cephalosporin market.

Leading companies in the cephalosporin market are actively developing new products and therapies, including advanced-generation cephalosporins, to combat antibiotic resistance and enhance their portfolio's effectiveness against a broader spectrum of bacterial infections. Ceftobiprole, a broad-spectrum cephalosporin antibiotic, is utilized to treat various bacterial infections, including skin and soft tissue infections and pneumonia. Mast Group Ltd. launched Ceftobiprole 5µg in the MASTDISCS Antimicrobial Susceptibility Test range in July 2022, offering a strong alternative for targeted empirical therapy due to its broad range of activity, effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), and favorable safety profile.

In October 2023, the Biomedical Advanced Research and Development Authority (BARDA), a US government department, partnered with Venatorx Pharmaceuticals Inc. This collaboration aims to accelerate the development of innovative medical countermeasures, building on BARDA's track record of supporting over 150 candidates through direct investments and its partnership with the CARB-X program. Venatorx Pharmaceuticals Inc. is a US-based pharmaceutical company focused on developing novel treatments, especially within the cephalosporin class, to combat antibiotic resistance.

Major companies operating in the cephalosporin market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Allergan PLC, Baxter International Inc., Eisai Co. Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Shionogi & Co Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Lupin Ltd., Zydus Lifesciences Ltd., Alkem Labs Ltd., Aurobindo Pharma Ltd., Fresenius Kabi, Aristo Pharmaceuticals Ltd., Accord Healthcare Ltd., Mankind Pharma Ltd., Qilu Anti Pharmaceutical Co. Ltd., Shandong Ruiying Pioneer Pharmaceutical Co. Ltd., Vansen Pharma Inc.

Asia-Pacific was the largest region in the cephalosporin market in 2024. The regions covered in the cephalosporin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cephalosporin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cephalosporin market consists of sales of cefazolin, cefuroxime, cefepime, and ceftriaxone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Cephalosporin refers to a class of broad-spectrum, semisynthetic-lactam antibiotics that are widely prescribed to treat diseases caused by both gram-positive and gram-negative bacteria. This class of antibiotics is commonly used to address various infections, including skin infections, strep throat, pneumonia, staph infections, tonsillitis, and bronchitis. Cephalosporins are particularly valuable for individuals allergic to penicillin, another common antibiotic.

The main types of cephalosporins are branded and generic. Branded cephalosporins are antibiotics marketed and sold under a specific brand name by pharmaceutical companies. They are utilized to treat infections caused by susceptible bacteria and can be administered via injection or oral routes. Branded cephalosporins find application in the treatment of respiratory tract infections, skin infections, ear infections, urinary tract infections, sexually transmitted infections, and other medical conditions.

The cephalosporin market research report is one of a series of new reports that provides cephalosporin market statistics, including cephalosporin industry global market size, regional shares, competitors with a cephalosporin market share, detailed cephalosporin market segments, market trends and opportunities, and any further data you may need to thrive in the cephalosporin industry. This cephalosporin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.